Delgocitinib

Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[6] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[6] Delgocitinib is a Janus kinase inhibitor that works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.